A Novel Simplified Endoscopic Score Using TXI, RDI, and NBI to Evaluate Ulcerative Colitis Activity and Predict Clinical Outcomes with Artificial Intelligence: the MONET Study
Led by University College Cork · Updated on 2024-12-03
300
Participants Needed
11
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
Sponsors
U
University College Cork
Lead Sponsor
O
Olympus
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are conducting an international multicenter study to develop a new simplified endoscopic score focused on vascular features of the colon to distinguish between inactive and mild inflammation in ulcerative colitis (UC). This study aims to compare the new score's ability to define disease activity and remission against existing endoscopic and histological scores, as well as to predict long-term clinical outcomes. Additionally, the study seeks to adapt artificial intelligence (AI) algorithms to enhance disease assessment and outcome prediction using various enhanced endoscopic techniques.
The study will use high-definition white light endoscopy (WLE-HD) along with texture and colour enhancement imaging (TXI), red dichromatic imaging (RDI), and narrow-band imaging (NBI) modes. It includes several phases: developing the score using video analysis and expert consensus, validating it in a large group of UC patients, assessing its reproducibility among gastroenterologists, and creating AI algorithms to standardize grading and prediction. Patients undergoing colonoscopy for disease assessment or surveillance will have colonoscopy with biopsies, blood and stool samples taken to monitor inflammation.
Participants will be followed up at 6 and 12 months with clinic or telephone assessments to evaluate disease activity using the Partial Mayo Score and clinical outcomes. Researchers will analyze the diagnostic performance of the new score within six months and correlate it with existing scores and AI developments over two years. The study involves collecting clinical data, imaging, biopsies, blood, and stool samples to thoroughly assess and predict UC disease activity and outcomes.
CONDITIONS
Brief Title
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis
Who Can Participate
Age: 18Years - 75Years
All Genders
Eligibility Criteria
You may qualify if you...
Adult patients aged 18 to 75 years old
Established diagnosis of ulcerative colitis for at least six months
Scheduled for endoscopy to assess disease activity or for cancer surveillance
You will not qualify if you...
Contraindications to endoscopy or biopsies, including toxic megacolon or severe blood clotting problems
Poor bowel preparation before endoscopy
Significant other health conditions limiting life expectancy or increasing endoscopy risk
Pregnant or breastfeeding
Unable to provide informed consent
Participation in an experimental trial completed less than 30 days ago
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Diagnostic Evaluation
Duration - Day of colonoscopy
Participants undergo colonoscopy with advanced imaging techniques and biopsies to assess disease activity and collect samples for research.
1 visit (in-person) for colonoscopy and sample collection
Long-term Monitoring
Duration - 12 months
Participants are followed up at 6 and 12 months to assess disease status and clinical outcomes using clinical evaluations and questionnaires.
2 visits (in-person or telephone) at 6 and 12 months post-colonoscopy
Intestinal Barrier Healing Is Superior to Endoscopic and Histologic Remission for Predicting Major Adverse Outcomes in Inflammatory Bowel Disease: The Prospective ERIca Trial.
A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis.
Marietta Iacucci, Rosanna Cannatelli, Tommaso L Parigi...